Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years
Objectives Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis. Methods A retrospective analysis of AML patients alive at least five years...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2022-12, Vol.109 (6), p.765-771 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 771 |
|---|---|
| container_issue | 6 |
| container_start_page | 765 |
| container_title | European journal of haematology |
| container_volume | 109 |
| creator | Heering, Gabriel Sasson, Maya Dominissini, Dan Shimoni, Avichai Avigdor, Abraham Nagler, Arnon Canaani, Jonathan |
| description | Objectives
Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis.
Methods
A retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis.
Results
The long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p |
| doi_str_mv | 10.1111/ejh.13864 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2716523240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716523240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1924-328812adf846a4a5eb7aff3b4860adb25cdd82c778e51a7bf2dcf3480975ac5e3</originalsourceid><addsrcrecordid>eNp10LFOwzAQgGELgUQpDLyBRxjS2o6TOCOqCgVVYoE5cpxL6-LEwU5asnVl4xn7JATKyi23fHfDj9A1JRM6zBQ26wkNRcxP0IjGhAQkJukpGpGUsIBzTs_RhfcbQghLaTJC65mtW6ga66TrMWyl6WSrbY1tiaXqWsBVD8bqAhvo3qDSEjcDgLr1eKfbNTa2Xh32Xy24CvvObfXwAsOHAih0vcLRYf_Zg3T-Ep2V0ni4-ttj9Ho_f5ktguXzw-PsbhkomjIehEwIymRRCh5LLiPIE1mWYc5FTGSRs0gVhWAqSQREVCZ5yQpVhlyQNImkiiAco5vj38bZ9w58m1XaKzBG1mA7n7GExhELGScDvT1S5az3DsqscboaOmSUZD81s6Fm9ltzsNOj3WkD_f8wmz8tjhffxld6uQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716523240</pqid></control><display><type>article</type><title>Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Heering, Gabriel ; Sasson, Maya ; Dominissini, Dan ; Shimoni, Avichai ; Avigdor, Abraham ; Nagler, Arnon ; Canaani, Jonathan</creator><creatorcontrib>Heering, Gabriel ; Sasson, Maya ; Dominissini, Dan ; Shimoni, Avichai ; Avigdor, Abraham ; Nagler, Arnon ; Canaani, Jonathan</creatorcontrib><description>Objectives
Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis.
Methods
A retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis.
Results
The long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p < 0.001], have a lower initial WBC count (OR, 0.58; 95% CI, 0.43–0.79; p = 0.0004), undergo an allogeneic stem cell transplantation (OR, 7.95; 95% CI, 3.07–20.59; p < 0.0001), and harbor favorable risk cytogenetics (OR, 0.03; 95% CI, 0.006–0.23; p = 0.0004).
Conclusions
Long‐term survival of AML is seen in a distinct demographic and biologic patient subset.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.13864</identifier><language>eng</language><subject>Acute myeloid leukemia ; ELN 2017 ; long‐term survival</subject><ispartof>European journal of haematology, 2022-12, Vol.109 (6), p.765-771</ispartof><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1924-328812adf846a4a5eb7aff3b4860adb25cdd82c778e51a7bf2dcf3480975ac5e3</cites><orcidid>0000-0002-5294-3524</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.13864$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.13864$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Heering, Gabriel</creatorcontrib><creatorcontrib>Sasson, Maya</creatorcontrib><creatorcontrib>Dominissini, Dan</creatorcontrib><creatorcontrib>Shimoni, Avichai</creatorcontrib><creatorcontrib>Avigdor, Abraham</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Canaani, Jonathan</creatorcontrib><title>Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years</title><title>European journal of haematology</title><description>Objectives
Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis.
Methods
A retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis.
Results
The long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p < 0.001], have a lower initial WBC count (OR, 0.58; 95% CI, 0.43–0.79; p = 0.0004), undergo an allogeneic stem cell transplantation (OR, 7.95; 95% CI, 3.07–20.59; p < 0.0001), and harbor favorable risk cytogenetics (OR, 0.03; 95% CI, 0.006–0.23; p = 0.0004).
Conclusions
Long‐term survival of AML is seen in a distinct demographic and biologic patient subset.</description><subject>Acute myeloid leukemia</subject><subject>ELN 2017</subject><subject>long‐term survival</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10LFOwzAQgGELgUQpDLyBRxjS2o6TOCOqCgVVYoE5cpxL6-LEwU5asnVl4xn7JATKyi23fHfDj9A1JRM6zBQ26wkNRcxP0IjGhAQkJukpGpGUsIBzTs_RhfcbQghLaTJC65mtW6ga66TrMWyl6WSrbY1tiaXqWsBVD8bqAhvo3qDSEjcDgLr1eKfbNTa2Xh32Xy24CvvObfXwAsOHAih0vcLRYf_Zg3T-Ep2V0ni4-ttj9Ho_f5ktguXzw-PsbhkomjIehEwIymRRCh5LLiPIE1mWYc5FTGSRs0gVhWAqSQREVCZ5yQpVhlyQNImkiiAco5vj38bZ9w58m1XaKzBG1mA7n7GExhELGScDvT1S5az3DsqscboaOmSUZD81s6Fm9ltzsNOj3WkD_f8wmz8tjhffxld6uQ</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Heering, Gabriel</creator><creator>Sasson, Maya</creator><creator>Dominissini, Dan</creator><creator>Shimoni, Avichai</creator><creator>Avigdor, Abraham</creator><creator>Nagler, Arnon</creator><creator>Canaani, Jonathan</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5294-3524</orcidid></search><sort><creationdate>202212</creationdate><title>Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years</title><author>Heering, Gabriel ; Sasson, Maya ; Dominissini, Dan ; Shimoni, Avichai ; Avigdor, Abraham ; Nagler, Arnon ; Canaani, Jonathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1924-328812adf846a4a5eb7aff3b4860adb25cdd82c778e51a7bf2dcf3480975ac5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute myeloid leukemia</topic><topic>ELN 2017</topic><topic>long‐term survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heering, Gabriel</creatorcontrib><creatorcontrib>Sasson, Maya</creatorcontrib><creatorcontrib>Dominissini, Dan</creatorcontrib><creatorcontrib>Shimoni, Avichai</creatorcontrib><creatorcontrib>Avigdor, Abraham</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Canaani, Jonathan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heering, Gabriel</au><au>Sasson, Maya</au><au>Dominissini, Dan</au><au>Shimoni, Avichai</au><au>Avigdor, Abraham</au><au>Nagler, Arnon</au><au>Canaani, Jonathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years</atitle><jtitle>European journal of haematology</jtitle><date>2022-12</date><risdate>2022</risdate><volume>109</volume><issue>6</issue><spage>765</spage><epage>771</epage><pages>765-771</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives
Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis.
Methods
A retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis.
Results
The long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p < 0.001], have a lower initial WBC count (OR, 0.58; 95% CI, 0.43–0.79; p = 0.0004), undergo an allogeneic stem cell transplantation (OR, 7.95; 95% CI, 3.07–20.59; p < 0.0001), and harbor favorable risk cytogenetics (OR, 0.03; 95% CI, 0.006–0.23; p = 0.0004).
Conclusions
Long‐term survival of AML is seen in a distinct demographic and biologic patient subset.</abstract><doi>10.1111/ejh.13864</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5294-3524</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2022-12, Vol.109 (6), p.765-771 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2716523240 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Acute myeloid leukemia ELN 2017 long‐term survival |
| title | Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A22%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contemporary%20evaluation%20of%20acute%20myeloid%20leukemia%20patients%20with%20long%E2%80%90term%20survival%20exceeding%205%E2%80%89years&rft.jtitle=European%20journal%20of%20haematology&rft.au=Heering,%20Gabriel&rft.date=2022-12&rft.volume=109&rft.issue=6&rft.spage=765&rft.epage=771&rft.pages=765-771&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.13864&rft_dat=%3Cproquest_cross%3E2716523240%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716523240&rft_id=info:pmid/&rfr_iscdi=true |